KR20100001169A - 하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 - Google Patents
하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 Download PDFInfo
- Publication number
- KR20100001169A KR20100001169A KR1020080060980A KR20080060980A KR20100001169A KR 20100001169 A KR20100001169 A KR 20100001169A KR 1020080060980 A KR1020080060980 A KR 1020080060980A KR 20080060980 A KR20080060980 A KR 20080060980A KR 20100001169 A KR20100001169 A KR 20100001169A
- Authority
- KR
- South Korea
- Prior art keywords
- foot
- mouth
- monoclonal antibody
- virus
- type
- Prior art date
Links
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 103
- 238000001514 detection method Methods 0.000 title claims abstract description 69
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 52
- 230000003472 neutralizing effect Effects 0.000 title claims description 77
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 51
- 241000700605 Viruses Species 0.000 claims abstract description 210
- 239000000427 antigen Substances 0.000 claims abstract description 119
- 102000036639 antigens Human genes 0.000 claims abstract description 119
- 108091007433 antigens Proteins 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000010530 Virus Neutralization Effects 0.000 claims abstract description 20
- 238000005406 washing Methods 0.000 claims abstract description 18
- 239000007787 solid Substances 0.000 claims abstract 5
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 40
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 39
- 239000007790 solid phase Substances 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 25
- 101710172711 Structural protein Proteins 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 13
- 238000010790 dilution Methods 0.000 claims description 12
- 239000012895 dilution Substances 0.000 claims description 12
- 230000003100 immobilizing effect Effects 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 230000001747 exhibiting effect Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 241000701447 unidentified baculovirus Species 0.000 claims description 9
- 230000001131 transforming effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000605 viral structure Anatomy 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101710188643 Non-structural protein 3c Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract description 10
- 101710197658 Capsid protein VP1 Proteins 0.000 description 50
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 50
- 101710132601 Capsid protein Proteins 0.000 description 48
- 101710108545 Viral protein 1 Proteins 0.000 description 48
- 238000012360 testing method Methods 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 6
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 241000709710 Swine vesicular disease virus Species 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000011962 continuous elektro deionisation Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940031418 trivalent vaccine Drugs 0.000 description 4
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 2
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 2
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- ZRZILYKEJBMFHY-BQBZGAKWSA-N Gly-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN ZRZILYKEJBMFHY-BQBZGAKWSA-N 0.000 description 2
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 2
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 2
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 2
- 101710106388 Structural protein VP1 Proteins 0.000 description 2
- XYEXCEPTALHNEV-RCWTZXSCSA-N Thr-Arg-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XYEXCEPTALHNEV-RCWTZXSCSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZBQCCTCQUCOXBO-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine Chemical compound CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 ZBQCCTCQUCOXBO-UHFFFAOYSA-N 0.000 description 1
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 1
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 1
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- OOIMKQRCPJBGPD-XUXIUFHCSA-N Arg-Ile-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O OOIMKQRCPJBGPD-XUXIUFHCSA-N 0.000 description 1
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 1
- CIBWFJFMOBIFTE-CIUDSAMLSA-N Asn-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N CIBWFJFMOBIFTE-CIUDSAMLSA-N 0.000 description 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 1
- HAJWYALLJIATCX-FXQIFTODSA-N Asn-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N HAJWYALLJIATCX-FXQIFTODSA-N 0.000 description 1
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 1
- QUMKPKWYDVMGNT-NUMRIWBASA-N Asn-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QUMKPKWYDVMGNT-NUMRIWBASA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000710194 Foot-and-mouth disease virus - type O Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- IHSGESFHTMFHRB-GUBZILKMSA-N Gln-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O IHSGESFHTMFHRB-GUBZILKMSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- NBWATNYAUVSAEQ-ZEILLAHLSA-N His-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O NBWATNYAUVSAEQ-ZEILLAHLSA-N 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- FZIJIFCXUCZHOL-CIUDSAMLSA-N Lys-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN FZIJIFCXUCZHOL-CIUDSAMLSA-N 0.000 description 1
- BDFHWFUAQLIMJO-KXNHARMFSA-N Lys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N)O BDFHWFUAQLIMJO-KXNHARMFSA-N 0.000 description 1
- XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 1
- 101710107904 NADH-ubiquinone oxidoreductase subunit 9 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710132845 Protein P1 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 1
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 1
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010025488 pinealon Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
- G01N2333/09—Foot-and-mouth disease virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
면역항원 | 단클론 항체 | 불활화 구제역 바이러스 항원 (O.D. 450nm) | 아형 | |||
O | A | Asia 1 | Control | |||
FMDV O VP1 Site A peptide(VP1-3) | 76.5E | 2.338 | 0.081 | 0.070 | 0.048 | IgG2a |
FMDV A VP1 Site A peptide(VP1-4) | 6G43 | 0.081 | 3.779 | 0.084 | 0.068 | IgG2b |
FMDV Vaccine | 70.17 | 0.811 | 1.072 | 0.915 | 0.091 | IgG1 |
단클론항체 | 구제역 바이러스 합성펩타이드 엘라이자(ELISA) | OVA | |||||||||||
O형 | A형 | Asia1형 | |||||||||||
VP1-1 | VP1-2 | VP1-3 | VP2 | VP3 | VP4 | VP1-4 | VP1-5 | VP1-6 | VP1-7 | VP1-8 | VP1-9 | ||
76.5E | 2.960 | 1.094 | 2.869 | 0.044 | 0.045 | 0.048 | 0.045 | 0.047 | 0.048 | 0.052 | 0.067 | 0.047 | 0.051 |
6G43 | 0.054 | 0.054 | 0.062 | 0.054 | 0.055 | 0.061 | 2.374 | 1.084 | 0.067 | 0.056 | 0.077 | 0.063 | 0.068 |
70.17 | 0.047 | 0.049 | 0.050 | 0.046 | 0.054 | 0.054 | 0.047 | 0.046 | 0.051 | 0.049 | 0.064 | 0.049 | 0.080 |
단클론항체 | 바이러스 중화 역가 | |||||
구제역 바이러스 혈청형 | ||||||
O/SKR/2000 | O/SKR/2002 | A22/Shamir | Asia1/Mongolisa/2005 | SVDV | VSV | |
76.5E | 256 | 724 | <16 | <16 | <16 | <16 |
6G43 | <16 | <16 | 64 | <16 | <16 | <16 |
70.17 | <16 | <16 | <16 | <16 | <16 | <16 |
단클론항체 | 불활화 구제역 바이러스 항체(O.D.450nm) | |||
O/SKR/2000 | O1 Manisa | A Iraq | Asia1/Shamir | |
76.5E | 0.719 | 0.775 | 0.299 | 0.305 |
6G43 | 0.314 | 0.289 | 1.024 | 0.987 |
70.17 | 1.140 | 1.569 | 1.167 | 1.159 |
Dilution factor | 유전자 재조합 구제역 바이러스 SP 항체(Batch 0501-01) | ||
O.D. | S/P | Unit | |
20 | 0.988 (S) | 1.01 | 20.3 |
40 | 0.561 (S) | 0.57 | 23.0 |
60 | 0.390 (S) | 0.40 | 24.0 |
80 | 0.286 (S) | 0.29 | 23.5 |
Virus(105.0TCID50/㎖)-대조군 | 0.975 (P) | 1.00 | 1.0 |
완충액 | 시약 조성 |
항체고정용액 | 1.0 M 비카보네이트(Bicarbobate); 0.5M 카보네이트(Carbonate); pH 9.0 |
세척액 | NaCl 0.137M; KH2PO4 1.4mM; Na2HPO4 7H2O 8.1mM; KCl 2.7mM; Detergent 0.05%, pH 7.4 |
블로킹 용액 | Tris- HCl 17.8mM; Tris-Base 2.2mM; NaCl 0.15M, Bovine Serum Albumin 5%; Gelatin 1%; Detergent 0.05%; pH 8.0 |
항원고정용액 | NaCl 0.137M; KH2PO4 1.4mM; Na2HPO4 7H2O 8.1mM; KCl 2.7mM; Bovine Serum Albumin 1%; pH 7.4 |
그룹 | 축종 | FMDV O AB ELISA | 민감도 | 특이도 | ||
양성혈청 | 음성혈청 | 계 | (%) | (%) | ||
양성 (N=154) | 소 | 106 | 1 | 107 | 99.1 | |
돼지 | 19 | 1 | 20 | 95.0 | ||
염소 | 21 | 1 | 22 | 95.5 | ||
양 | 3 | 0 | 3 | 100.0 | ||
기타 | 2 | 0 | 2 | 100.0 | ||
계/평균 | 151 | 3 | 154 | 98.1 | ||
음성 (N=384) | 소 | 1 | 127 | 128 | 99.2 | |
돼지 | 0 | 149 | 149 | 100.0 | ||
염소 | 0 | 65 | 65 | 100.0 | ||
양 | 4 | 27 | 31 | 87.1 | ||
사슴 | 0 | 11 | 11 | 100.0 | ||
계/평균 | 5 | 379 | 384 | 98.7 |
그룹 | 축종 | CEDI FMDV O AB ELISA | 민감도 | 특이도 | ||
양성혈청 | 음성혈청 | 계 | (%) | (%) | ||
양성 (N=76) | 소 | 29 | 0 | 29 | 100.0 | |
돼지 | 18 | 2 | 20 | 90.0 | ||
염소 | 22 | 0 | 22 | 100.0 | ||
양 | 3 | 0 | 3 | 100.0 | ||
기타 | 2 | 0 | 2 | 100.0 | ||
계/평균 | 74 | 2 | 76 | 97.4 | ||
음성 (N=34) | 소 | 0 | 13 | 13 | 100.0 | |
돼지 | 0 | 4 | 4 | 100.0 | ||
염소 | 0 | 11 | 11 | 100.0 | ||
양 | 1 | 5 | 6 | 83.3 | ||
계/평균 | 1 | 33 | 34 | 97.1 |
그룹 | 중화항체 역가 | FMDV O AB ELISA | CEDI FMDV Type O ELISA | ||||||
양성 | 음성 | 계 | 양성 | 음성 | 계 | 양성 | 음성 | 계 | |
Positive | 113 | 0 | 113 | 112 | 1 | 113 | 34 | 1 | 35 |
Cut-off | 0 | 40 | 40 | 26 | 14 | 40 | 28 | 11 | 39 |
Total | 113 | 40 | 153 | 138 | 15 | 153 | 62 | 12 | 74 |
%Positive | 73.9 | 90.2 | 83.8 |
Serum | SNT against FMDV O | 엄 등에 의한 방법 | FMDV O AB ELISA (본 발명) | ||||
OD | SN | 결과 | OD | SN | 결과 | ||
SM01 | 512 | 0.291 | 0.25 | 양성 | 0.086 | 0.10 | 양성 |
SM02 | 512 | 0.371 | 0.32 | 양성 | 0.086 | 0.10 | 양성 |
ST01 | 128 | 0.672 | 0.57 | 양성 | 0.213 | 0.24 | 양성 |
ST02 | 128 | 2.072 | 1.76 | 음성 | 0.273 | 0.30 | 양성 |
PC | 0.111 | 0.09 | 0.1035 | 0.11 | |||
NC | 1.176 | 1.00 | 0.9045 | 1.00 |
FMDV A AB ELISA | SNT against FMDV A Serotype | ||||||||
1024 | 512 | 256 | 128 | 64 | 32 | 16 | 8 | 0 | |
OD | 0.116 | 0.155 | 0.254 | 0.472 | 0.859 | 1.141 | 1.381 | 1.535 | 1.617 |
S/N | 0.07 | 0.10 | 0.16 | 0.29 | 0.53 | 0.71 | 0.85 | 0.95 | 1.00 |
Claims (20)
- 구제역 바이러스 O형, A형 및 Asia 1형에 공통적인 면역반응성을 나타내는 단클론항체를 생산함을 특징으로 하는 하이브리도마 세포주(KCTC 11337BP).
- 제 1 항의 하이브리도마 세포주에 의해 생산되는 단클론항체.
- 구제역 바이러스 O형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체를 생산함을 특징으로 하는 하이브리도마 세포주(KCTC 11319BP).
- 제 3 항의 하이브리도마 세포주에 의해 생산되는 단클론항체.
- 구제역 바이러스 A형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체를 생산함을 특징으로 하는 하이브리도마 세포주(KCTC 11318BP).
- 제 5 항의 하이브리도마 세포주에 의해 생산되는 단클론항체.
- 진단용 항원, 상기 진단용 항원 포획을 위한 단클론항체, 검출표지, 상기 검출표지가 결합되는 단클론항체 및 상기 검출표지의 활성 측정용 시약을 함유하는 구제역 진단 시약에 있어서,상기 진단용 항원 포획을 위한 단클론항체는 구제역 바이러스 O형, A형 및 Asia 1형에 공통적인 면역반응성을 나타내는 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 7 항에 있어서,상기 구제역 바이러스 O형, A형 및 Asia 1형에 공통적인 면역반응성을 나타내는 단클론항체는 제 2 항의 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 7 항에 있어서,상기 검출표지가 결합되는 단클론항체는 구제역 바이러스 O형 VP1 사이트 A 에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체 또는 구제역 바이러스 A형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 9 항에 있어서,상기 구제역 바이러스 O형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체는 서열목록 1 내지 3의 아미노산 서열로 표시되는 에피토프 중에서 선택되는 어느 하나 이상의 에피토프에 특이적으로 반응하는 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 9 항에 있어서,상기 구제역 바이러스 O형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체는 제 4 항의 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 9 항에 있어서,상기 구제역 바이러스 A형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이 러스 중화능을 나타내는 단클론항체는 서열목록 7 내지 9의 아미노산 서열로 표시되는 에피토프 중에서 선택되는 어느 하나 이상의 에피토프에 특이적으로 반응하는 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 9 항에 있어서,상기 구제역 바이러스 A형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체는 제 6 항의 단클론항체인 것을 특징으로 하는 구제역 진단 시약.
- 제 9 항에 있어서,상기 진단용 항원은 구제역바이러스를 구성하는 구조단백질 VP1, VP2, VP3 및 VP4를 코딩하는 유전자와 비구조단백질인 3C 유전자를 적어도 포함하는 재조합베큘로바이러스를 숙주세포에 형질전환시켜 제조된 재조합 구제역 바이러스 구조단백질인 것을 특징으로 하는 구제역 진단 시약.
- 제 7 항 내지 제 14 항 중 어느 한 항의 구제역 진단 시약을 포함하는 구제역 진단 키트.
- 고체상 지지체에 항원 포획을 위한 단클론항체를 고정시키는 단계;상기 고체상 지지체에 부착되지 않은 항체들을 세척하여 제거하는 단계;상기 고체상 지지체에 구제역 바이러스 진단용 항원을 반응시켜 고정시키는 단계;상기 고체상 지지체에 부착되지 않은 항원들을 세척하여 제거하는 단계; 및검출표지가 결합된 단클론항체를 고체상 지지체에 고정된 상기 구제역 바이러스 진단용 항원과 반응시키는 단계를 포함하고,상기 항원 포획을 위한 단클론항체는 구제역 바이러스 O형, A형 및 Asia 1형에 공통적인 면역반응성을 나타내는 단클론항체인 것을 특징으로 하는 구제역 바이러스 중화항체 검출방법.
- 제 16 항에 있어서,상기 검출표지가 결합된 단클론항체에 사용되는 단클론항체는 구제역 바이러스 O형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체 또는 구제역 바이러스 A형 VP1 사이트 A에 대한 특이적인 면역반응성과 바이러스 중화능을 나타내는 단클론항체인 것을 특징으로 하는 구제역 바이러스 중화항체 검출방법.
- 제 17 항에 있어서,상기 구제역 바이러스 진단용 항원은 구조단백질 VP1, VP2, VP3 및 VP4를 코딩하는 유전자와 비구조단백질인 3C 유전자를 적어도 포함하는 재조합베큘로바이러스를 숙주세포에 형질전환시켜 제조된 재조합 구제역 바이러스 구조단백질인 것을 특징으로 하는 구제역 바이러스 중화항체 검출방법.
- 제 18 항에 있어서,상기 재조합 구제역 바이러스 구조단백질은,바이러스 역가가 측정된 구제역 바이러스를 대조군으로 하고, 상기 재조합 구제역 바이러스 구조단백질을 실험군으로 하여, 상기 재조합 구제역 바이러스 구조단백질의 항원활성도를 산출하여 정량적으로 첨가된 것을 특징으로 하는 구제역 바이러스 중화항체 검출방법.
- 제 18 항에 있어서,상기 재조합 구제역 바이러스 구조단백질은,상기 고체상 지지체에 상기 항원 포획을 위한 단클론항체를 고정시킨 다음, 대조군으로 바이러스 역가(T)가 측정된 구제역 바이러스 항원과 반응시켜 항원-항체 복합체를 형성하고, 상기 항원-항체 복합체에 상기 검출표지가 결합된 단클론항체를 반응시켜 상기 대조군의 검출결과값(P)을 측정하고,실험군으로 상기 바이러스 역가(T)가 측정된 구제역 바이러스 대신 상기 재조합 구제역 바이러스 구조단백질을 일정 희석배수로 희석하여, 상기 고체상 지지체에 상기 항원 포획을 위한 단클론항체를 고정시킨 다음, 상기 희석된 재조합 구제역 바이러스 구조단백질과 반응시켜 항원-항체 복합체를 형성하고, 상기 항원-항체 복합체에 상기 검출표지가 결합된 단클론항체를 반응시켜 상기 실험군의 검출결과값(S)을 측정한 다음,하기의 계산식으로부터 항원활성도(Tx)를 산출하여, 상기 재조합 구제역 바이러스 구조단백질의 희석배수에 따른 상기 항원활성도의 평균값으로부터 상기 재조합 구제역 바이러스 구조단백질의 유효 항원량을 정하여 첨가된 것을 특징으로 하는 구제역 바이러스 중화항체 검출방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080060980A KR101102841B1 (ko) | 2008-06-26 | 2008-06-26 | 하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080060980A KR101102841B1 (ko) | 2008-06-26 | 2008-06-26 | 하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100001169A true KR20100001169A (ko) | 2010-01-06 |
KR101102841B1 KR101102841B1 (ko) | 2012-01-05 |
Family
ID=41811495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080060980A KR101102841B1 (ko) | 2008-06-26 | 2008-06-26 | 하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101102841B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101873204B1 (ko) * | 2016-12-12 | 2018-07-12 | 대한민국 | 구제역 바이러스 입자 판별 방법 |
KR102008609B1 (ko) | 2018-01-29 | 2019-10-21 | 충북대학교 산학협력단 | 지카 바이러스의 비구조단백질 1에 대한 특이 항체를 생산하는 하이브리도마 및 이로부터 생성된 항체, 이의 용도 |
KR20200121426A (ko) * | 2019-04-15 | 2020-10-26 | 주식회사 바이오노트 | 구제역 바이러스 o형에 면역 반응성을 나타내는 항체를 이용한 구제역 백신 접종으로 생성된 항체를 검출하는 방법 |
KR20210016850A (ko) * | 2019-08-05 | 2021-02-17 | 한국생명공학연구원 | 구제역 바이러스 검출용 단일클론항체 및 이의 용도 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100737446B1 (ko) * | 2004-11-23 | 2007-07-09 | 대한민국 | 구제역바이러스 구조단백질 유전자를 함유하는재조합베큘로바이러스 및 이를 이용한 재조합 단백질의제조방법 |
-
2008
- 2008-06-26 KR KR1020080060980A patent/KR101102841B1/ko active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101873204B1 (ko) * | 2016-12-12 | 2018-07-12 | 대한민국 | 구제역 바이러스 입자 판별 방법 |
KR102008609B1 (ko) | 2018-01-29 | 2019-10-21 | 충북대학교 산학협력단 | 지카 바이러스의 비구조단백질 1에 대한 특이 항체를 생산하는 하이브리도마 및 이로부터 생성된 항체, 이의 용도 |
KR20200121426A (ko) * | 2019-04-15 | 2020-10-26 | 주식회사 바이오노트 | 구제역 바이러스 o형에 면역 반응성을 나타내는 항체를 이용한 구제역 백신 접종으로 생성된 항체를 검출하는 방법 |
KR20210016850A (ko) * | 2019-08-05 | 2021-02-17 | 한국생명공학연구원 | 구제역 바이러스 검출용 단일클론항체 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
KR101102841B1 (ko) | 2012-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chénard et al. | A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology | |
Lin et al. | Development and application of an indirect ELISA for the detection of antibodies to porcine epidemic diarrhea virus based on a recombinant spike protein | |
TW202200603A (zh) | 對抗sars-cov-2之結構蛋白質之抗體之抗原決定區、和該抗原決定區反應之抗體、使用該抗體檢測sars-cov-2之方法、含有該抗體之sars-cov-2檢測套組、檢測含有該抗原決定區之多胜肽之抗sars-cov-2抗體之方法、含有該抗原決定區之多胜肽之抗sars-cov-2抗體檢測套組、含有該抗原決定區之多胜肽之sars-cov-2用疫苗以及含有該抗體之sars-cov-2傳染病治療藥 | |
Okumura et al. | Development of serological assays for Thottapalayam virus, an insectivore-borne Hantavirus | |
US10035841B2 (en) | Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3ABC and uses thereof | |
Yu et al. | Establishment of a blocking ELISA detection method for against African swine fever virus p30 antibody | |
WO2012163263A1 (en) | Reagents and methods for prrsv detection | |
Chen et al. | A type-specific blocking ELISA for the detection of infectious bronchitis virus antibody | |
Kubickova et al. | A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen | |
KR101102841B1 (ko) | 하이브리도마 세포주, 이에 의해 생산된 단클론항체,구제역 진단 시약, 진단 키트 및 구제역 바이러스 중화항체검출방법 | |
CN108918869B (zh) | fiber2蛋白及其重组蛋白在检测血清4型禽腺病毒抗体方面的应用 | |
CN109320606B (zh) | 一种特异性结合口蹄疫非结构蛋白的单克隆抗体及其应用 | |
CN105296435B (zh) | 杂交瘤细胞株及其分泌的抗口蹄疫o型(o/gx/09-7)病毒的特异性单克隆抗体与应用 | |
Du et al. | Development and application of an indirect ELISA for the detection of gp45 antibodies to equine infectious anemia virus | |
Hosamani et al. | A new blocking ELISA for detection of foot-and-mouth disease non-structural protein (NSP) antibodies in a broad host range | |
Yang et al. | Production of monoclonal antibodies against whole virus particles of foot-and-mouth disease virus serotype O and A and their potential use in quantification of intact virus for vaccine manufacture | |
Xu et al. | Identification of a conservative site in the African swine fever virus p54 protein and its preliminary application in a serological assay | |
Liu et al. | Identification of three linear B cell epitopes against non-structural protein 3ABC of FMDV using monoclonal antibodies | |
Mallick et al. | Production and characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and development of a sandwich ELISA for virus antigen detection | |
CN111398594A (zh) | 一种特异性检测黄热病毒ns1抗原的免疫诊断试剂盒 | |
Cai et al. | Detection of asymptomatic antigenemia in pigs infected by porcine reproductive and respiratory syndrome virus (PRRSV) by a novel capture immunoassay with monoclonal antibodies against the nucleocapsid protein of PRRSV | |
KR20070046390A (ko) | 구제역 바이러스 3ab 비구조단백질과 이에 특이적으로반응하는 단일클론 항체 및 이들의 조합을 이용한 구제역바이러스의 비구조단백질 항체 검사 또는 구제역의 진단방법 | |
CN113999293B (zh) | 一种特异性结合新型冠状病毒s蛋白的抗体及其应用 | |
Shapouri et al. | A novel competitive ELISA for detection of antibodies against bovine viral diarrhea virus infection | |
CN114685619B (zh) | 一种抗原蛋白、其单克隆抗体或多克隆抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141024 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151126 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161026 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171127 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 9 |